Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus whole-brain radiotherapy for untreated brain metastases from lung cancer
ChiCTR1900022834Phase 2Not yet recruiting
- Sponsor
- Department of Radiation Oncology, Third Affiliated Hospital of Soochow University
- Start
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in bronchial carcinoma and brain metastases, sponsored by Department of Radiation Oncology, Third Affiliated Hospital of Soochow University. Primary endpoints: Intracranial tumor progression-free survival time and Early and late adverse events. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
bronchial carcinomabrain metastases
Beyond the preview
Go deeper on ChiCTR1900022834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022834.